Capital Fund Management (CFM)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Capital Fund Management (CFM)’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-36,572	Closed	-$300K	–	2329
2023 Q3	$419K	Buy	36,572 +7,372	+25%	+$142K	﹤0.01%	1823
2023 Q2	$739K	Buy	+29,200	New	+$910K	﹤0.01%	1490
2023 Q1	–	Sell	-16,900	Closed	-$312K	–	1774
2022 Q4	$312K	Buy	+16,900	New	+$387K	﹤0.01%	1334
2020 Q4	–	Sell	-13,943	Closed	-$351K	–	1609
2020 Q3	$351K	Buy	+13,943	New	+$366K	﹤0.01%	1100

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s RVNC Position: Q4 2023 in Review

Capital Fund Management (CFM) sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 36,572 shares — an estimated $300K sold.

Capital Fund Management (CFM) first reported a position in RVNC in Q3 2020 and held it in 4 quarters. The position peaked at $739K in Q2 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

Capital Fund Management (CFM) reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
Capital Fund Management (CFM) sold 36,572 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $300K.
Capital Fund Management (CFM) first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 4 quarters.
Capital Fund Management (CFM)'s Revance Therapeutics, Inc. position peaked at $739K in Q2 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2023, filed 14 Feb 2024.